With a deep pipeline of 25 therapeutics and therapeutic candidates, PureTech leverages its expertise in biology and the interface between brain, immune, and gut systems to target conditions such as cancer, neurological disorders, and gastrointestinal diseases. The company has received FDA clearance and European marketing authorization for two of its therapies. PureTech's approach mitigates risk by strategically allocating resources to its most successful programs, and its extensive network of scientists and advisors provides access to groundbreaking science.